Longboard Pharmaceuticals, Inc. Common Stock
LBPH
LBPH was delisted on the 29th of November, 2024.
125 hedge funds and large institutions have $1.33B invested in Longboard Pharmaceuticals, Inc. Common Stock in 2024 Q3 according to their latest regulatory filings, with 35 funds opening new positions, 54 increasing their positions, 28 reducing their positions, and 10 closing their positions.
250% more first-time investments, than exits
New positions opened: 35 | Existing positions closed: 10
112% more call options, than puts
Call options by funds: $989K | Put options by funds: $466K
93% more repeat investments, than reductions
Existing positions increased: 54 | Existing positions reduced: 28
27% more capital invested
Capital invested by funds: $1.05B → $1.33B (+$278M)
25% more funds holding
Funds holding: 100 → 125 (+25)
20% less funds holding in top 10
Funds holding in top 10: 5 → 4 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
WP
Woodline Partners
San Francisco,
California
|
+$32.4M |
| 2 |
Goldman Sachs
New York
|
+$24.2M |
| 3 |
BlackRock
New York
|
+$16.2M |
| 4 |
EA
Emerald Advisers
Leola,
Pennsylvania
|
+$15.7M |
| 5 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$13.8M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RCM
RA Capital Management
Boston,
Massachusetts
|
-$88.9M |
| 2 |
Point72 Asset Management
Stamford,
Connecticut
|
-$27.9M |
| 3 |
JP Morgan Chase
New York
|
-$17.5M |
| 4 |
PCH
Polar Capital Holdings
London,
United Kingdom
|
-$8.67M |
| 5 |
PHP
Parkman Healthcare Partners
Stamford,
Connecticut
|
-$6.99M |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
B
126
Braidwell
Stamford,
Connecticut
| – | -$5.57M | -205,926 | Closed |
|
|
LCM
127
Lynx1 Capital Management
San Juan,
Puerto Rico
| – | -$4.52M | -167,317 | Closed |
|
|
ECM
128
ExodusPoint Capital Management
New York
| – | -$2.18M | -80,514 | Closed |
|
|
LCM
129
Laurion Capital Management
New York
| – | -$1.79M | -66,149 | Closed |
|
|
YIH
130
Y-Intercept (HK)
Hong Kong
| – | -$574K | -21,242 | Closed |
|
131
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
| – | -$277K | -8,032 | Closed |
|
|
SC
132
Shay Capital
New York
| – | -$203K | -7,500 | Closed |
|
|
C
133
Covestor
London,
United Kingdom
| – | +$103 | +3 | New |
|
|
CAL
134
Capital Advisors Ltd
Shaker Heights,
Ohio
| – | +$310 | +9 | New |
|
135
Carson Wealth (CWM LLC)
Omaha,
Nebraska
| – | +$448 | +13 | +1,300% |
|
LBPH Hedge Fund Activity: Q3 2024 in Review
125 of the 6,964 institutional investors tracked by Wall St. Rank reported a position in Longboard Pharmaceuticals, Inc. Common Stock (LBPH) for Q3 2024, worth a combined $1.33B — up 27% from $1.05B a quarter earlier.
Buyers outnumbered sellers: 35 funds opened new LBPH positions and 10 closed out — a net gain of 25 holders — while 54 added to existing stakes and 28 trimmed.
The largest buyer was Woodline Partners, adding an estimated $32.4M. The largest seller was RA Capital Management, exiting entirely with an estimated $88.9M sold.
- 125 institutional investors held Longboard Pharmaceuticals, Inc. Common Stock (LBPH) as of Q3 2024, up from 100 in Q2 2024.
- Funds reported $1.33B of Longboard Pharmaceuticals, Inc. Common Stock stock for Q3 2024, up 27% quarter-over-quarter.
- 35 funds opened new Longboard Pharmaceuticals, Inc. Common Stock positions in Q3 2024 and 10 closed out, a net change of +25 holders.
- The largest Longboard Pharmaceuticals, Inc. Common Stock buyer in Q3 2024 was Woodline Partners, an estimated $32.4M added.
- The largest Longboard Pharmaceuticals, Inc. Common Stock seller in Q3 2024 was RA Capital Management, an estimated $88.9M sold.
Based on aggregated 13F filings for Q3 2024.